Clinical Trial Update: A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease [Phase 1]

View source ↗

Summary

Phase I trial of ZD1694 (Tomudex), a thymidylate synthase inhibitor, in pediatric patients with advanced neoplastic disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Tomudex (ZD1694)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasm | Phase 1 | Status: COMPLETED